ES2058199T3 - Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih. - Google Patents

Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.

Info

Publication number
ES2058199T3
ES2058199T3 ES88115607T ES88115607T ES2058199T3 ES 2058199 T3 ES2058199 T3 ES 2058199T3 ES 88115607 T ES88115607 T ES 88115607T ES 88115607 T ES88115607 T ES 88115607T ES 2058199 T3 ES2058199 T3 ES 2058199T3
Authority
ES
Spain
Prior art keywords
hiv
cell
infected
infected cells
individuals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88115607T
Other languages
English (en)
Inventor
Joyce M Zarling
Jeffrey A Ledbetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2058199T3 publication Critical patent/ES2058199T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION RELACIONADA CON NUEVOS ANTICUERPOS HETEROCONJUGADOS Y SUS USOS EN METODOS PARA MATAR CELULAS INFECTADAS DE HIV. LOS HETEROCONJUGADOS SE COMPRENDEN EN UN ANTICUERPO ESPECIFICO PARA UN ANTIGENO HIV QUE SE EXPRESA EN CELULAS INFECTADAS DE HIV LINKER CONRADAS A UN ANTICUERPO ESPECIFICO PARA UNA CELULA EFECTORA DE LA SANGRE PERIFERICA CAPAZ DE MATAR UNA CELULA BLANCO INFECTADA HIV. EL ANTICUERPO HETEROCONJUGADO DE LA INVENCION DE LA CELULA BLANCO FISICAMENTE EFECTORA A LA CELULA Y PUEDE ACTIVAR EL MECANISMO LITICO DE LA CELULA EFECTORA EN LA MUERTE DE LA CELULA BLANCO INFECTADA DE HIV. LOS METODOS, HETEROCONJUGADOS, COMBINACIONES FARMACEUTICAS SE DESCRIBEN EN ELLA PROVEER UN NUEVO APROVECHAMIENTO AL TRATAMIENTO DE LOS INDIVIDUOS INFECTADOS DE HIV POR AMPLIFICACION ENDOGENA DEL MECANISMO EFECTOR ESPECIFICO HIV Y PUEDE TENER VALOR PROFILACTICO EN INDIVIDUOS INFECTADOS RECIENTEMENTE O EXPUESTOS AL VIRUS HIV ACCIDENTALMENTE
ES88115607T 1987-09-23 1988-09-22 Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih. Expired - Lifetime ES2058199T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10015787A 1987-09-23 1987-09-23

Publications (1)

Publication Number Publication Date
ES2058199T3 true ES2058199T3 (es) 1994-11-01

Family

ID=22278371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88115607T Expired - Lifetime ES2058199T3 (es) 1987-09-23 1988-09-22 Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.

Country Status (8)

Country Link
EP (1) EP0308936B1 (es)
JP (1) JP2755395B2 (es)
AT (1) ATE108068T1 (es)
AU (1) AU629180B2 (es)
CA (1) CA1338518C (es)
DE (1) DE3850542T2 (es)
ES (1) ES2058199T3 (es)
HK (1) HK110594A (es)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5897861A (en) * 1989-06-29 1999-04-27 Medarex, Inc. Bispecific reagents for AIDS therapy
ES2096590T3 (es) * 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
AU667460B2 (en) * 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
CA2063035A1 (en) * 1991-03-27 1992-09-28 Klaus Karjalainen Chimaeric antibodies containing the ligand domain of cd4
EP0580758A4 (en) * 1991-04-18 1995-04-05 Sinai School Medicine RECOMBINANT ANTIBODIES AGAINST HUMAN IMMUNE WEAKNESS VIRUS.
AU5322494A (en) 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
EP2083079A1 (en) 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
ES2298905T3 (es) 1997-10-17 2008-05-16 Genentech, Inc. Homologos de tipo toll humanos.
EP2014770A3 (en) 1997-10-29 2009-02-18 Genentech, Inc. WNT-1 Iinduced secreted polypeptide WISP-2
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6740739B1 (en) 1998-01-15 2004-05-25 Genentech, Inc. Substitutional variants of APO-2 ligand
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
DE69939374D1 (de) 1998-03-17 2008-10-02 Genentech Inc Zu vegf und bmp1 homologe polypeptide
EP2058334B1 (en) 1998-06-12 2012-10-31 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP2075335A3 (en) 1998-12-22 2009-09-30 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1978029A3 (en) 1999-06-15 2008-10-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
CA2411102A1 (en) 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE60129695T2 (de) 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PT1383785E (pt) 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
WO2003088808A2 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
MXPA05013181A (es) 2003-06-06 2006-06-23 Genentech Inc Metodos y composiciones para modular hgf/met.
SI2295073T1 (sl) 2003-11-17 2014-07-31 Genentech, Inc. Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
PL1706428T3 (pl) 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2007081608A2 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
BRPI0620648B1 (pt) 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
ATE491948T1 (de) 2006-02-06 2011-01-15 Rhode Island Hospital Gpr30-östrogenrezeptor bei mammakarzinomen
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2520935A3 (en) 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
KR20090078349A (ko) 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
EP2421896A1 (en) 2009-04-22 2012-02-29 Merck Patent GmbH Antibody fusion proteins with modified fcrn binding sites
MX346115B (es) 2009-08-06 2017-03-08 Genentech Inc * Metodo para mejorar la eliminación de virus en la purificacion proteica.
JP5787891B2 (ja) 2009-09-01 2015-09-30 ジェネンテック， インコーポレイテッド 改変されたプロテインａ溶離による向上したタンパク質精製
MX368790B (es) 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
EP4492053A3 (en) 2010-05-25 2025-03-19 F. Hoffmann-La Roche AG Methods of purifying polypeptides
PL2576580T3 (pl) 2010-05-28 2017-03-31 F.Hoffmann-La Roche Ag Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
CN105051528A (zh) 2012-11-15 2015-11-11 弗·哈夫曼-拉罗切有限公司 离子强度介导的pH梯度离子交换色谱
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
CN110538322A (zh) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
JP6676521B2 (ja) 2013-03-14 2020-04-08 マクロジェニクス，インコーポレーテッド 二重特異性分子、薬学的組成物及びそれらの使用
SI2970875T2 (sl) 2013-03-15 2026-03-31 F. Hoffmann-La Roche Ag Sestavki celičnih kultur z antioksidanti in postopki za proizvodnjo polipeptidov
EP2983710B1 (en) 2013-04-09 2019-07-31 Annexon, Inc. Methods of treatment for neuromyelitis optica
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
AU2014287044B2 (en) 2013-07-12 2020-02-06 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
RU2016112549A (ru) 2013-09-05 2017-10-10 Дженентек, Инк. Способ для повторного использования хроматографии
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
KR102366644B1 (ko) 2014-05-30 2022-02-22 상하이 헨리우스 바이오테크, 인크. 항-표피 성장 인자 수용체 (egfr) 항체
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
EP3201227A4 (en) 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
US10112994B2 (en) 2014-11-05 2018-10-30 Genentech, Inc. Methods of producing two chain proteins in bacteria
MX382952B (es) 2014-11-05 2025-03-13 Genentech Inc Métodos de producción de proteínas de cadena doble en bacterias.
HUE070383T2 (hu) 2014-11-05 2025-06-28 Annexon Inc Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
CN107646038B (zh) 2015-05-28 2021-08-20 基因泰克公司 用于检测抗cd3同二聚体的基于细胞的测定
EP3763827A1 (en) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
HRP20211528T1 (hr) 2015-10-25 2021-12-24 Sanofi Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije
CA3003458A1 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
HRP20250951T1 (hr) 2015-12-30 2025-10-10 F. Hoffmann-La Roche Ag Formulacije sa smanjenom razgradnjom polisorbata
CN109073635A (zh) 2016-01-25 2018-12-21 豪夫迈·罗氏有限公司 用于测定t细胞依赖性双特异性抗体的方法
IL262241B2 (en) 2016-04-13 2024-05-01 Sanofi Sa Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
HRP20231188T1 (hr) 2016-04-13 2024-02-02 Sanofi Trispecifični i/ili trovalentni vezujući proteini
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
HUE071741T2 (hu) 2016-08-15 2025-09-28 Hoffmann La Roche Nem-ionos felületaktív anyag mennyiségi meghatározására szolgáló kromatográfiás eljárás a nem-ionos felületaktív anyagot és polipeptidet tartalmazó összetételben
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3565845A4 (en) 2017-01-06 2020-10-07 Biosion, Inc. ERBB2 ANTIBODIES AND THEIR USES
IL270138B2 (en) 2017-04-26 2025-08-01 Eureka Therapeutics Inc Structures that specifically recognize glypican 3 and their uses
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
KR102733407B1 (ko) 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
CA3078800A1 (en) 2017-10-10 2019-04-18 Sanofi Anti-cd38 antibodies and methods of use
TW201930358A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
CA3092345A1 (en) 2018-03-13 2019-09-19 The Regents Of The University Of California Inhibitors of integrin alpha 2 beta 1 and methods of use
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
SG11202012342WA (en) 2018-06-18 2021-01-28 Eureka Therapeutics Inc Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
JP7535495B2 (ja) 2018-07-27 2024-08-16 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－５抗体及びその使用方法
MX2021002299A (es) 2018-08-31 2021-04-28 Alector Llc Anticuerpos de anti-cd33 y metodos para usarlos.
CA3115679A1 (en) 2018-10-09 2020-04-16 Sanofi Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
WO2020214963A1 (en) 2019-04-18 2020-10-22 Genentech, Inc. Antibody potency assay
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
EP4073119A1 (en) 2019-12-12 2022-10-19 Alector LLC Methods of use of anti-cd33 antibodies
AU2021264016A1 (en) 2020-05-01 2022-11-24 Shangpharma Innovation Inc. Inhibitors of alpha 2 beta 1 integrin and methods of use thereof
US12006550B2 (en) 2020-10-12 2024-06-11 University Of South Carolina Targeting treatment for ADAM30 in pathological cells
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
WO2023245105A1 (en) 2022-06-17 2023-12-21 Genentech, Inc. Use of kosmotropes to enhance yield of an affinity chromatography purification step

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1213229A (en) * 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor
EP0180171B1 (en) * 1984-10-31 1992-04-08 Massachusetts Institute Of Technology Process for making a targeted cell susceptible to lysis by cytotoxic t lymphocytes
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies

Also Published As

Publication number Publication date
JPH01163134A (ja) 1989-06-27
AU2279988A (en) 1989-03-23
DE3850542D1 (de) 1994-08-11
EP0308936A2 (en) 1989-03-29
AU629180B2 (en) 1992-10-01
ATE108068T1 (de) 1994-07-15
EP0308936B1 (en) 1994-07-06
CA1338518C (en) 1996-08-13
EP0308936A3 (en) 1990-02-14
DE3850542T2 (de) 1994-11-24
HK110594A (en) 1994-10-21
JP2755395B2 (ja) 1998-05-20

Similar Documents

Publication Publication Date Title
ES2058199T3 (es) Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
ES2139017T3 (es) Compuestos que inhiben la replicacion del vih.
Duncan et al. High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy
Bonaparte et al. Inability of natural killer cells to destroy autologous HIV-infected T lymphocytes
ES2126620T3 (es) Retrovirus del grupo de los vih y su utilizacion.
ES2067457T3 (es) Celula de origen animal con una proteina antigenica introducida en ella.
EA200300336A1 (ru) Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
ES2097759T3 (es) Anticuerpos especificos para el dominio de fijacion de cd4 de hiv.
ES2192200T3 (es) Intercambiador de especificidad de antigenos/anticuerpos.
ES2050114T3 (es) Anticuerpos monoclonales humanos para el virus asociado a la linfoadenopatia.
Özkaya Şahin et al. Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection
Ceccarelli et al. Unusual signs and symptoms in HIV-positive patients coinfected with Leishmania spp: The importance of neglected tropical disease in differential diagnosis
Barnable et al. MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model
Laumaea et al. COVID‐19 vaccine humoral response in frequent platelet donors with plateletpheresis‐associated lymphopenia
Omi et al. Inhibition of R 5‐tropic HIV type‐1 replication in CD 4+ natural killer T cells by γδ T lymphocytes
Bui et al. Schistosoma mansoni soluble egg antigens enhance Listeria monocytogenes vector HIV-1 vaccine induction of cytotoxic T cells
Cummins et al. Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cells
Su et al. exploring antibody potential as prophylactic/therapeutic strategies for prevention of early mucosal HIV-1 infection
Suslov Transient immunosuppression during short interruption of HAART: Another key to HIV cure in the “Berlin patient”?
Kim et al. SARS-CoV-2 ORF8 limits expression levels of Spike antigen
Nair et al. Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2
GB334531A (en) Improvements in bleaching methods and compositions
Pereson et al. Evaluation of T Cell Immune Memory Response after Sinopharm (BBIBP-CorV), Gam-COVID-Vac (Sputnik V), and Heterologous Sputnik-V/mRNA-1273 (Moderna) COVID-19 Vaccination Schemes against Different SARS-CoV-2 Variants
ES2085908T3 (es) Antigenos de la glucoproteina transmembranica de cubierta de un retrovirus humano del tipo hiv-2 (antigenos que presentan entre ellos un parentesco inmunologico).
SU72255A1 (ru) Препарат дл уничтожени перхоти

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 308936

Country of ref document: ES